Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2019

View Archived Issues

Tonix, Massachusetts General Hospital enter collaboration to develop MAb for transplant rejection

Scioto Biosciences receives NIH grant to develop novel probiotic therapy

Model recapitulates anti-NMDA receptor encephalitis via active immunization

Neglected neuraminidase may explain flu vaccine failures

TREM2 may play role in AD patients without risk variant

Muscle-generated BDNF found to control metabolic flexibility

Approved calcium channel antagonists identified for repurposing to treat Pitt Hopkins Syndrome

Zebrafish screening platform can identify therapeutics for spinal cord injury

Allergan enrolling in phase III long-term extension study of brazikumab for Crohn's disease

Rocket announces clearance for phase II registration-enabling FANCOLEN-II study of RP-L102

Phase III FORT study of fosmetpantotenate does not meet primary endpoint

Zydus initiates phase II EVIDENCES VII study of saroglitazar magnesium in NAFLD with PCOS

Novel mouse model of human optic atrophy syndrome

Phase I results for AZD-1775 plus gemcitabine in locally advanced pancreatic cancer

CARB-X funds development of vaccine against carbapenem-resistant superbug Klebsiella pneumoniae

New tubulin polymerization inhibitors identified at the University of Sydney

Medshine Discovery identifies Janus kinase inhibitors

High affinity nerve growth factor receptor inhibitors patented by Shanghai GeneChem

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine disclose F2RL3 antagonists

Sunshine Lake Pharma discovers sodium/glucose cotransporter 1 inhibitors

HMPL-523 begins phase I trial in China for ITP

DREAMM-2 study of belantamab mafodotin in relapsed multiple myeloma meets primary objective

FDA accepts Seelos' IND for phase IIb/III study of SLS-005 for MPS III

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...